We are dedicated to delivering first-in-class cancer cell-directed therapies, and boldly pursuing innovative strategies in immuno-oncology, as well as designing smart combinations.
Explore the videos and materials below to learn more about how Boehringer Ingelheim are taking cancer on.
Xentuzumab (BI 836845), VEGF/ANG2 inhibitor (BI 836880), MDM2-p53 antagonist (BI 907828), BET inhibitor (BI 894999), PD-1 inhibitor (BI 754091), LAG-3 inhibitor (BI754111), SMAC mimetic (BI 891065), LRP5/6 antagonist (BI 905677), SIRPα myeloid checkpoint inhibitor (BI 765063), SOS1::KRAS inhibitor (BI 1701963), mRNA vaccine (BI 1361849) are investigational compounds and have not been approved. Their safety and efficacy have not been established.
Page last updated: October 2019
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue